Editas Medicine (EDIT) Posts Q1 GAAP Loss of 80c/Share

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), which may not compare with the analyst estimate of ($0.30). Revenue for the quarter came in at $805 thousand versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• CLSA Reiterates Outperform (2) Rating on CSL Ltd. (CSL:AU) (CMXHF)
• Faraday Future unveils nine robotics devices priced from $9,990